Interleukin-6 (IL-6) Inhibitors Therapeutics Global Pipeline Analysis Report 2017 - Clinical Trials & Results, Patents, Designations, and Collaborations
DUBLIN, March 15, 2018 /PRNewswire/ --
The "Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" report has been added to ResearchAndMarkets.com's offering.
The study analyzed that the IL-6 inhibitors therapeutics pipeline comprises approximately 18 active drug candidates in different stages of development. Interleukin-6 inhibitors acts on the IL-6 receptor. IL-6 receptors belong to a group of cytokine receptors that are expressed by leukocytes and plays an important role in the functioning of the immune system. It has a characteristic role in systemic inflammation in numerous disease conditions, including rheumatoid arthritis, and psoriatic arthritis.
According to the research findings, most of the drug candidates of the IL-16 inhibitors are being developed as the monoclonal antibody.
The positive clinical results from IL-6 inhibitors drug candidates have been driving the pipeline growth. GlaxoSmithKline plc presented results from two pivotal Phase III studies (NCT01606761; NCT02019472) evaluating subcutaneous sirukumab. In both the studies, sirukumab met the primary endpoint showing significant improvement in the signs and symptoms of moderately to severely active rheumatoid arthritis compared to placebo.
In January 2017, Tiziana Life Sciences plc acquired an exclusive world-wide license for NI-1201, a fully human anti-IL-6R monoclonal antibody (mAb), from Novimmune SA. In exchange for the exclusive license from Novimmune SA, Tiziana Life Sciences plc agreed to an upfront cash payment, milestone payments, and a royalty on future sales.
Report Segmentation
- By Phase
- By Molecule Type
- By Route of Administration
- By Company
Key Topics Covered:
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
Chapter 3. Executive Summary
Chapter 4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company
Chapter 5. Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline Analysis by Phase (2017)
5.1 Filed: Drug profiles
5.1.3 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase III: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase II: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
Phase I: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.4 Pre-Clinical: Drug profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Strategic Development
5.3.4 Designation
5.3.5 Grants
5.3.6 Patent
5.3.7 Technology
5.5 Discovery: Drug profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Strategic Development
5.3.4 Designation
5.3.5 Grants
5.3.6 Patent
5.3.7 Technology
Chapter 6. Clinical Trials Analysis
6.1 Clinical Trials by Region for IL-6 Inhibitors Therapeutics Pipeline
6.2 Clinical Trials by Trial Status for IL-6 Inhibitors Therapeutics Pipeline
Chapter 7. Competitive Landscape
7.1 Key Players Benchmarking for IL-6 Inhibitors Therapeutics Pipeline
7.2 SWOT Analysis of IL-6 Inhibitors Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats
Chapter 8. Company Profiles
- Chugai Pharmaceutical Co. Ltd.
- GlaxoSmithKline Plc
- Vitaeris Inc.
For more information about this report visit https://www.researchandmarkets.com/research/g3hqbd/interleukin6?w=5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article